Related Experiment Video
Updated: Oct 21, 2025
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Advances in Research on Bladder Cancer Targeting Peptides: a Review
Abstract:
Bladder cancer (Bca) is the second most common malignant tumor of the genitourinary system in Chinese male population with high potential of recurrence and progression. The overall prognosis has not been improved significantly for the past 30 years due to the lack of early theranostic technique. Currently the early theranostic technique for bladder cancer is mainly through the intravesical approach, but the clinical outcomes are poor due to the limited tumor-targeting efficiency. Therefore, the targeting peptides for bladder cancer provide possibility to advance intravesical theranostic technique. However, no systematic review has covered the wide use of the targeting peptides for intravesical theranostic techniques in bladder cancer. Herein, a summary of original researches introduces all aspects of the targeting peptides for bladder cancer, including the peptide screening, the targeting mechanism and its preclinical application.
Insights
Targeting peptides offer a promising advancement for bladder cancer (Bca) intravesical theranostic techniques, improving tumor-targeting efficiency and patient outcomes. This review summarizes peptide screening, mechanisms, and preclinical applications for Bca.
Area of Science:
- Oncology
- Biotechnology
- Urology
Background:
- Bladder cancer (Bca) is a prevalent genitourinary malignancy in Chinese males, characterized by high recurrence and progression rates.
- Despite decades of research, the prognosis for Bca has seen limited improvement due to the absence of effective early theranostic techniques.
- Current intravesical theranostic approaches for Bca suffer from poor clinical outcomes attributed to insufficient tumor-targeting efficiency.
Purpose of the Study:
- To systematically review the application of targeting peptides in intravesical theranostic techniques for bladder cancer.
- To provide a comprehensive summary of original research on targeting peptides for Bca.
- To explore peptide screening, targeting mechanisms, and preclinical applications for Bca theranostics.
Main Methods:
- Systematic review of original research studies.
- Analysis of peptide screening methodologies for Bca targeting.
- Evaluation of targeting mechanisms and preclinical applications of peptides in Bca models.
Main Results:
- Targeting peptides demonstrate potential to enhance tumor-targeting efficiency in intravesical Bca theranostics.
- Various peptide screening strategies have been employed to identify Bca-specific peptides.
- Preclinical studies highlight the feasibility of using targeting peptides for Bca diagnosis and therapy.
Conclusions:
- Targeting peptides represent a significant advancement for improving intravesical theranostic techniques in bladder cancer.
- Further research and clinical translation of these peptides are warranted to improve Bca patient prognosis.
- The development of effective targeting peptides could revolutionize early detection and treatment of bladder cancer.
